Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

AIDS

Volumn 19, Issue 14, 2005, Pages 1443-1448

  Lalezari, Jacob ^a   Thompson, Melanie ^b   Kumar, Priny ^c   Piliero, Peter ^d   Davey, Richard ^e   Patterson, Kristine ^f   Shachoy Clark, Anne ^g   Adkison, Kimberly ^g   Demarest, James ^g   Lou, Yu ^g   Berrey, Michelle ^g   Piscitelli, Stephen ^g  

^a Quest Clinical Research   (United States)

^b ARCA   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

873140; CCR5; HIV infection; Pharmacokinetics; Tropism

Indexed keywords

873140; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VIRUS LOAD;

EID: 25844450042     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000183633.06580.8a     Document Type: Article

References (11)

1. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
2. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-188.
3. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogensis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20:111-126.
4. Pierson TC, Doms RW, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004; 14:255-270.
5. Demarest J, Shibayama S, Ferris R, Vavro C, St Clair M, Boone L. A novel CCR5 antagonist, 873140, exhibits potent in vitro anti-HIV activity. XV International Conference on AIDS. Bangkok, July 2004 [abstract WeOA1231].
6. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005; 67:1268-1282.
7. Pozniak AL, Fatkenheuer C, Johnson M, Moepelman LM, Rockstroh J, Goebel F, et al. Effect of short term monotherapy with UK-427,857 on viral load in HIV-infected patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 2003 [abstract H-443].
8. Schurmann D, Rouzier R, Nougarede R, Reynes J, Fatkenheuer G, Raffi R, et al. SCH D: Antiviral activity of a CCR5 receptor antagonist. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 140LB].
9. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. JAIDS 2003; 32:18-29.
10. Rousseau FS, Wakeford C, Mommeja-Marin H, Sanne I, Moxham C, Harris J, et al. FTC-102 Clinical Trial Group. Prospective randomized trial of emtricitabine versus lamivudme short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 2003; 188:1652-1658.
11. Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M Jr, Kunstman K, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003; 198:1551-1562.